News

The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

CymaBay Submits New Drug Application to FDA for Approval of Seladelpar in Primary Biliary Cholangitis Treatment

Saturday, December 16, 2023

CymaBay Therapeutics Inc has achieved a notable milestone in advancing innovative therapies for liver and chronic diseases The biopharmaceutical company has officially submitted a New Drug Application

AC Immune's Immunotherapy Targeting Anti-pTau Advances to Phase 2b Trial for Alzheimer's Disease

Saturday, December 16, 2023

AC Immune SA has revealed the commencement of a Phase b clinical trial to assess ACI in patients with preclinical Alzheimers disease AD those who are not yet displaying symptoms

Terray Therapeutics and Bristol Myers Squibb Announce Collaborative Partnership on Multiple Targets

Friday, December 15, 2023

Terray Therapeutics a biotechnology company has announced a collaborative agreement with Bristol Myers Squibb to discover and develop small molecule therapeutics

Maze Therapeutics Initiates Phase 1 Trial for MZE829, an Oral APOL1 Inhibitor, Targeting APOL1 Kidney Disease

Friday, December 15, 2023

Maze Therapeutics has announced the initiation of dosing in the Phase trial of MZE in healthy volunteers MZE is an oral small molecule designed to inhibit apolipoprotein L

Kyverna Therapeutics Has Been Granted FDA Fast Track Designation for KYV-101 in the Treatment of Individuals With Refractory Myasthenia Gravis

Thursday, December 14, 2023

Kyverna Therapeutics a clinicalstage biopharmaceutical company focused on developing cell therapies for autoimmune diseases has received fast track designation from the US Food and Drug Administration

Vergent Bioscience Launches Phase 2 VISUALIZE Study for VGT-309 in Lung Cancer Surgeries

Thursday, December 14, 2023

Vergent Bioscience a biotechnology company in the clinical stage is progressing with the enrollment of the initial cohort of patients for a Phase multicenter study This study focuses on evaluating the safety and effectiveness of VGT

Depixus and Daiichi Sankyo Establish Strategic Collaboration Utilizing MAGNA™ Technology to Expedite RNA-targeted Drug Discovery

Wednesday, December 13, 2023

Depixus an innovator in the field of interactomics has entered into a collaboration with Daiichi Sankyo to apply their novel MAGNA technology to expedite the Japanese healthcare leaders RNAtargeted drug

RoslinCT poised to manufacture the inaugural FDA-approved CRISPR-based gene therapy, CASGEVY™ (Exagamglogene Autotemcel), in the United States

Tuesday, December 12, 2023

RoslinCT a Contract Development and Manufacturing Organization specializing in cell and gene therapy is set to produce the inaugural CRISPRbased gene therapy approved by the US Food and Drug Administration

Maridose Introduces Innovative CRO Collective for Advancing Development of Cannabis-Based Pharmaceuticals

Tuesday, December 12, 2023

Maridose a leading manufacturer licensed by the DEA and specializing in cannabisbased products is excited to introduce its innovative Contract Research Organization group This newly formed unit is dedicated to collaborating

Glycomine Marks a Significant Milestone as the First Pediatric Patient Receives Dosing in Phase 2 of the Clinical Study for GLM101, a Prospective Treatment for PMM2-CDG

Tuesday, December 12, 2023

Glycomine Inc a biotechnology company in the clinical stage has recently announced the initiation of dosing in the first pediatric patient for a multicenter openlabel Phase study of GLM